Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Samsung Bioepis Nudges Closer To Ranibizumab Approvals With New Data

Similarity Data To Be Presented At 2021 ARVO Meeting

Executive Summary

Samsung Bioepis has been tight-lipped on the potential to win approval for its SB11 biosimilar ranibizumab product this year, though new similarity data is a further positive omen for the Korea-based biosimilar player.

You may also be interested in...



Samsung Bioepis Scoops First EU Lucentis Biosimilar As 2022 Date Looms

Samsung Bioepis has seen a positive opinion in the EU for its Byooviz (ranibizumab) biosimilar treatment for wet age-related macular degeneration turned into final approval by the European Commission. The company is also leading the pack in the US.

Samsung Bioepis Backed By EMA For First Lucentis Biosimilar

Samsung Bioepis is set to make waves with the first ophthalmic biosimilar after the European regulator recommended that its ranibizumab biosimilar Byooviz receive a pan-European marketing authorization.

Xbrane Sets Cash Target Ahead Of Lucentis Ambitions In 2022

Swedish developer Xbrane Biopharma has identified a timeline to turn its cash flows positive, with plans to roll-out biosimilar Lucentis next year.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150889

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel